<DOC>
	<DOCNO>NCT01363310</DOCNO>
	<brief_summary>Most individual major depressive disorder manifest clinically significant agitation . Concurrent agitation depress individual associate intensification mood symptom , decrease probability recovery , increase recurrence risk , suicidality , increase medical-service utilization . The occurrence anxiety/agitation phenomenology depress patient often invite need augmentation strategy ( e.g . atypical antipsychotic , benzodiazepine , etc . ) complicate polypharmacy regimen . Moreover , individual major depressive disorder often report worsen symptom severity , irritability , hostility , dysphoria , significant subjective distress ( This response pattern similar individual bipolar disorder ) . Results large research study provide evidence indicate quetiapine capable offering clinically significant multidimensional symptom relief bipolar depression . Moreover , result several trial major depressive disorder generalize anxiety disorder establish efficacy quetiapine therapy unipolar depression anxiety syndrome . So far , atypical antipsychotic agent evaluate specifically treatment agitated depression . In study , hypothesize person major depressive disorder prominent agitation ( i.e . agitate depression ) exhibit favourable response tolerability profile quetiapine XR compare escitalopram .</brief_summary>
	<brief_title>The Quietude Study : Quetiapine Use Agitated Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Male female Age 18 65 Outpatient enrolment A diagnosis major depressive disorder Baseline HAMD17 score &gt; 20 HAMD Item1 score &gt; 2 enrolment baseline Significant agitation CGIS score &gt; 4 screen baseline Negative serum pregnancy test enrolment use reliable method birth control study Able understand comply requirement study Able willing give meaningful inform write consent Another Axis I diagnosis primary focus within 6 month enrolment Axis II disorder cause impact current diagnosis Current depressive episode &lt; 4 week , &gt; 12 month Substance alcohol abuse dependency define DSM IV within 6 month enrolment Any pervasive developmental disorder dementing disorder Treatment antipsychotic , mood stabilizer psychoactive drug le 7 day prior randomization Treatment fluoxetine le 28 day prior baseline Treatment MAO inhibitor , anxiolytic drug excess 2 mg lorazepam equivalents/day . Insufficient response two antidepressant index episode prior study involvement Known lack antidepressant response quetiapine dose least 50 mg/day x 4 week Known lack antidepressant response escitalopram dose least 10 mg/day Known intolerance hypersensitivity quetiapine escitalopram Treatment Electroconvulsive therapy within 90 day prior baseline Use Potent P450 3A4 inhibitor inducer within 14 day baseline AST &amp; ALT ≥ 3X ULN TSH ≥ 10 % ULN Unstable medical condition Medical condition would affect absorption , distribution , metabolism excretion study treatment Significant ECG abnormalities Pregnancy lactation Patients increase suicidal risk , HAMD item 3 ≥3 make suicide attempt within past 6 month . Patients , investigator opinion , require psychotherapy ( supportive psychotherapy ) study period , unless psychotherapy ongoing minimum 3 month prior randomisation A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrolment glycosylated haemoglobin ( HbA1c ) &gt; 8.5 % . Admitted hospital treatment DM DM relate illness past 12 week . Not physician care DM . Physician responsible patient 's DM care indicate patient 's DM control . Physician responsible patient 's DM care approve patient 's participation study Has dose oral hypoglycaemic drug ( ) and/or diet 4 week prior randomisation . For thiazolidinediones ( glitazones ) period le 8 week . Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week Note : If diabetic patient meet one criterion , patient exclude even treat physician believe patient stable participate study Clinically significant deviation reference range clinical laboratory test result An absolute neutrophil count ( ANC ) 1.5 x 109 per liter Those involve planning and/or conduct study enrol subject Previous enrolment randomization present study Participation another medication trial within 4 week prior enrolment study herein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>